ArticleCase reports in dermatology
Successful Treatment of Refractory Erythroderma with Abrocitinib: A Case Report.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Erythroderma represents a severe dermatological condition often challenging to treat, especially in cases unresponsive to standard therapies. Currently, evidence for the use of abrocitinib in this setting is limited, leaving a gap in available treatment options. Case Presentation: We report the case of an adult patient with refractory erythroderma who failed to respond to conventional treatments, including glucocorticoids, immunosuppressants, and biologics. To manage the acute flare, abrocitinib was initiated alongside a tapering course of glucocorticoids. Over the treatment course, the patient demonstrated significant clinical improvement, including reduction in erythema, associated symptoms, and hair regrowth. Importantly, the glucocorticoids were successfully discontinued, and no recurrence or serious adverse events were observed during a 6-month follow-up. Conclusion: This case indicates that abrocitinib may be a promising therapeutic option for patients with erythroderma resistant to existing treatments. Further research with larger patient cohorts is necessary to establish its efficacy and safety in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.